HSBC/CALL/GILEAD SCIENCES/70/0.1/15.01.25 | Real-time BOERSE MUENCHEN 03:35:47 2024-06-27 pm EDT | ||
| 0.47 EUR | -6.00% |
|
| Current month | +117.39% | ||
| 1 month | +78.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.47 | -6.00% |
| 24-06-26 | 0.5 | -3.85% |
| 24-06-25 | 0.52 | -14.75% |
| 24-06-24 | 0.61 | +3.39% |
| 24-06-21 | 0.59 | +15.69% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 03:35 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | HS0PR0 |
| ISIN | DE000HS0PR04 |
| Date issued | 2023-07-14 |
| Strike | 70 $ |
| Maturity | 2025-01-15 (202 Days) |
| Parity | 10 : 1 |
| Emission price | 1.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.88 € |
|---|---|
| Lowest since issue | 0.21 € |
| Spread | 0.02 € |
| Spread % | 4.35% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.31
USD
Average target price
82.97
USD
Spread / Average Target
+19.70%
- Stock Market
- Warrants
- Warrant
